mutLBSgeneDB |
Gene summary for B4GALT7 |
![]() |
Basic gene Info. | Gene symbol | B4GALT7 |
Gene name | xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 | |
Synonyms | EDSP1|XGALT1|XGPT1 | |
Cytomap | UCSC genome browser: 5q35.2-q35.3 | |
Type of gene | protein-coding | |
RefGenes | NM_007255.2, | |
Description | UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 7UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 7beta-1,4-GalTase 7beta-1,4-galactosyltransferase 7beta-1,4-galactosyltransferase VIIbeta4Gal-T7beta4GalT-VIIgalactosyltransfe | |
Modification date | 20141215 | |
dbXrefs | MIM : 604327 | |
HGNC : HGNC | ||
Ensembl : ENSG00000027847 | ||
HPRD : 05060 | ||
Vega : OTTHUMG00000130851 | ||
Protein | UniProt: Q9UBV7 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_B4GALT7 | |
BioGPS: 11285 | ||
Pathway | NCI Pathway Interaction Database: B4GALT7 | |
KEGG: B4GALT7 | ||
REACTOME: B4GALT7 | ||
Pathway Commons: B4GALT7 | ||
Context | iHOP: B4GALT7 | |
ligand binding site mutation search in PubMed: B4GALT7 | ||
UCL Cancer Institute: B4GALT7 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID | GO:0006024 | glycosaminoglycan biosynthetic process | 10438455 | GO:0006487 | protein N-linked glycosylation | 24052259 |
Top |
Ligand binding site mutations for B4GALT7 |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | H257 | R256H | STAD | 1 | R104 | E106K | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for B4GALT7 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | H257 | R256H | -1.0176896 | R104 | E106K | -0.069398583 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for B4GALT7 |
![]() |
![]() |
Top |
Top |
Phenotype information for B4GALT7 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C1869122 | Ehlers-Danlos syndrome, progeroid form | 3 | Biomarker, GeneticVariation |
umls:C0376634 | Craniofacial Abnormalities | 1 | Biomarker |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for B4GALT7 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | MN | MANGANESE(2+) | 4irp | A | H257 | MN | MANGANESE(2+) | 4irp | B | H257 | MN | MANGANESE(2+) | 4irq | A | H257 | MN | MANGANESE(2+) | 4irq | B | H257 | MN | MANGANESE(2+) | 4irq | C | H257 | MN | MANGANESE(2+) | 4irq | D | H257 | UDP | URIDINE-DIPHOSPHATE | 4irp | A | R104 | UDP | URIDINE-DIPHOSPHATE | 4irp | B | R104 | UDP | URIDINE-DIPHOSPHATE | 4irq | A | R104 H257 | UDP | URIDINE-DIPHOSPHATE | 4irq | B | R104 H257 | UDP | URIDINE-DIPHOSPHATE | 4irq | C | R104 H257 | UDP | URIDINE-DIPHOSPHATE | 4irq | D | R104 H257 |
Top |
Conservation information for LBS of B4GALT7 |
![]() |
LBS | AA sequence | # species | Species | D163 | YIAMHDVDLLP | 2 | Homo sapiens, Mus musculus | D163 | YMVMNDVDLLP | 1 | Caenorhabditis elegans | D165 | AMHDVDLLPLN | 2 | Homo sapiens, Mus musculus | D165 | VMNDVDLLPVN | 1 | Caenorhabditis elegans | F101 | AVLVPFRERFE | 2 | Homo sapiens, Mus musculus | F101 | CVIVPYRDRLE | 1 | Caenorhabditis elegans | F139 | VDHFRFNRAAL | 2 | Homo sapiens, Mus musculus | F139 | TDPLRFNRASL | 1 | Caenorhabditis elegans | H257 | YKTFRHLHDPA | 1 | Homo sapiens | H257 | YQTFRHLHDPA | 1 | Mus musculus | H257 | SNTFRHIHGPK | 1 | Caenorhabditis elegans | H259 | TFRHLHDPAWR | 2 | Homo sapiens, Mus musculus | H259 | TFRHIHGPK-R | 1 | Caenorhabditis elegans | P100 | LAVLVPFRERF | 2 | Homo sapiens, Mus musculus | P100 | LCVIVPYRDRL | 1 | Caenorhabditis elegans | R102 | VLVPFRERFEE | 2 | Homo sapiens, Mus musculus | R102 | VIVPYRDRLEE | 1 | Caenorhabditis elegans | R104 | VPFRERFEELL | 2 | Homo sapiens, Mus musculus | R104 | VPYRDRLEELR | 1 | Caenorhabditis elegans | R266 | PAWRKRD---Q | 2 | Homo sapiens, Mus musculus | R266 | PK-RKRDYTPK | 1 | Caenorhabditis elegans | V164 | IAMHDVDLLPL | 2 | Homo sapiens, Mus musculus | V164 | MVMNDVDLLPV | 1 | Caenorhabditis elegans | W224 | NRFWGWGREDD | 2 | Homo sapiens, Mus musculus | W224 | NKYWGWGLEDD | 1 | Caenorhabditis elegans | Y194 | ELHPLYHYKTY | 2 | Homo sapiens, Mus musculus | Y194 | QYHPKYHYEKF | 1 | Caenorhabditis elegans |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |